Credit Suisse Ag Satsuma Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $348,422 - $526,263	-72,588 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$4.57 - $7.18 $450,611 - $707,962	-98,602 Reduced 57.6%	72,588 $429,000
Q4 2020 Feb 12, 2021	BUY	$3.56 - $5.09 $112,912 - $161,439	31,717 Added 22.74%	171,190 $789,000
Q3 2020 Nov 13, 2020	BUY	$3.85 - $28.47 $536,971 - $3.97 Million	139,473 New	139,473 $543,000
Q2 2020 Aug 12, 2020	SELL	$16.01 - $34.69 $869,278 - $1.88 Million	-54,296 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$14.53 - $30.69 $4,736 - $10,004	326 Added 0.6%	54,296 $1.17 Million
Q4 2019 Feb 12, 2020	SELL	$9.32 - $19.68 $2.37 Million - $5.01 Million	-254,614 Reduced 82.51%	53,970 $1.06 Million
Q3 2019 Nov 12, 2019	BUY	$14.98 - $16.9 $4.62 Million - $5.22 Million	308,584 New	308,584 $4.63 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.